AAPL   381.63 (+0.07%)
MSFT   212.30 (-0.25%)
GOOGL   1,504.91 (+0.09%)
AMZN   3,106.62 (+0.83%)
BABA   258.34 (+0.26%)
MU   49.35 (-0.72%)
GE   6.66 (-3.06%)
TSLA   1,373.65 (+0.57%)
T   29.49 (-3.22%)
ACB   11.57 (-4.85%)
F   5.89 (-3.45%)
GILD   74.45 (-1.53%)
BAC   22.53 (-2.47%)
AAPL   381.63 (+0.07%)
MSFT   212.30 (-0.25%)
GOOGL   1,504.91 (+0.09%)
AMZN   3,106.62 (+0.83%)
BABA   258.34 (+0.26%)
MU   49.35 (-0.72%)
GE   6.66 (-3.06%)
TSLA   1,373.65 (+0.57%)
T   29.49 (-3.22%)
ACB   11.57 (-4.85%)
F   5.89 (-3.45%)
GILD   74.45 (-1.53%)
BAC   22.53 (-2.47%)
AAPL   381.63 (+0.07%)
MSFT   212.30 (-0.25%)
GOOGL   1,504.91 (+0.09%)
AMZN   3,106.62 (+0.83%)
BABA   258.34 (+0.26%)
MU   49.35 (-0.72%)
GE   6.66 (-3.06%)
TSLA   1,373.65 (+0.57%)
T   29.49 (-3.22%)
ACB   11.57 (-4.85%)
F   5.89 (-3.45%)
GILD   74.45 (-1.53%)
BAC   22.53 (-2.47%)
AAPL   381.63 (+0.07%)
MSFT   212.30 (-0.25%)
GOOGL   1,504.91 (+0.09%)
AMZN   3,106.62 (+0.83%)
BABA   258.34 (+0.26%)
MU   49.35 (-0.72%)
GE   6.66 (-3.06%)
TSLA   1,373.65 (+0.57%)
T   29.49 (-3.22%)
ACB   11.57 (-4.85%)
F   5.89 (-3.45%)
GILD   74.45 (-1.53%)
BAC   22.53 (-2.47%)
Log in

NYSE:SNYSanofi Stock Price, Forecast & News

$50.34
-1.18 (-2.29 %)
(As of 07/9/2020 11:36 AM ET)
Add
Compare
Today's Range
$50.32
Now: $50.34
$51.28
50-Day Range
$47.20
MA: $50.16
$52.50
52-Week Range
$37.62
Now: $50.34
$52.94
Volume10,826 shs
Average Volume2.15 million shs
Market Capitalization$126.06 billion
P/E Ratio16.08
Dividend Yield2.27%
Beta0.67
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Read More
Sanofi logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.3Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone33-1-53-77-44-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$39.60 billion
Cash Flow$5.53 per share
Book Value$26.11 per share

Profitability

Net Income$4.28 billion

Miscellaneous

EmployeesN/A
Outstanding Shares2,504,138,000
Market Cap$126.06 billion
Next Earnings Date7/29/2020 (Confirmed)
OptionableOptionable

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

Sanofi (NYSE:SNY) Frequently Asked Questions

How has Sanofi's stock been impacted by COVID-19 (Coronavirus)?

Sanofi's stock was trading at $44.79 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SNY stock has increased by 12.4% and is now trading at $50.34. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sanofi?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sanofi.

When is Sanofi's next earnings date?

Sanofi is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Sanofi.

How were Sanofi's earnings last quarter?

Sanofi SA (NYSE:SNY) released its quarterly earnings results on Friday, April, 24th. The company reported $0.90 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.76 by $0.14. The business had revenue of $9.90 billion for the quarter, compared to analyst estimates of $9.64 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. View Sanofi's earnings history.

What guidance has Sanofi issued on next quarter's earnings?

Sanofi issued an update on its FY 2020 Pre-Market earnings guidance on Friday, April, 24th. The company provided earnings per share guidance of 6.81-6.87 for the period.

What price target have analysts set for SNY?

12 analysts have issued twelve-month target prices for Sanofi's shares. Their forecasts range from $52.00 to $58.00. On average, they expect Sanofi's share price to reach $55.33 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price. View analysts' price targets for Sanofi.

Has Sanofi been receiving favorable news coverage?

News articles about SNY stock have been trending negative on Thursday, according to InfoTrie. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Sanofi earned a daily sentiment score of -2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about Sanofi.

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Gilead Sciences (GILD), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Walt Disney (DIS), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), AT&T (T) and Merck & Co., Inc. (MRK).

Who are Sanofi's key executives?

Sanofi's management team includes the following people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 62)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a variety of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.02%), Foundation Resource Management Inc. (0.01%), Thomasville National Bank (0.00%), Stonebridge Capital Management Inc. (0.00%), Clarius Group LLC (0.00%) and Arden Trust Co (0.00%). View institutional ownership trends for Sanofi.

Which institutional investors are selling Sanofi stock?

SNY stock was sold by a variety of institutional investors in the last quarter, including Foundation Resource Management Inc., and Stonebridge Capital Management Inc.. View insider buying and selling activity for Sanofi.

Which institutional investors are buying Sanofi stock?

SNY stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Arden Trust Co, Ellevest Inc., Thomasville National Bank, and Clarius Group LLC. View insider buying and selling activity for Sanofi.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $50.34.

How big of a company is Sanofi?

Sanofi has a market capitalization of $126.06 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis.

What is Sanofi's official website?

The official website for Sanofi is www.sanofi.com.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.